Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Luteal phase support in "in vitro fertilization" (IVF) cycles has been shown to improve
pregnancy rates and became a standard of treatment, and progesterone is the first choice
considering its safety profile and effectiveness. There are many studies demonstrating that
vaginal progesterone is equally efficacious and better tolerated compared to intramuscular
progesterone for luteal phase support in IVF cycles. Conversely, although different studies
showed that subcutaneous progesterone is equally efficacious compared to vaginal
progesterone, patient use satisfaction and compliance were less studied with few evidences
are available, that may guide the choice of vaginal progesterone instead of subcutaneous
progesterone and other way around. Considering the paucity of published data about the
patient's preference and use satisfaction about subcutaneous progesterone, the investigators
will conduct a prospective randomized study aimed to compared adverse effects rates, impact
on quality of life, use satisfaction and administration preference in women undergoing luteal
phase support with vaginal progesterone versus subcutaneous progesterone during IVF cycles,
that may guide the choice for luteal phase support in IVF cycles.